Keros Therapeutics, Inc.
NASDAQ:KROS
14.21 (USD) • At close April 25, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Assets: | |||||||
| Current Assets: | |||||||
| Cash & Cash Equivalents
| 559.931 | 331.147 | 279.048 | 230.042 | 265.876 | 7.02 | 23.259 |
| Short Term Investments
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 559.931 | 331.147 | 279.048 | 230.042 | 265.876 | 7.02 | 23.259 |
| Net Receivables
| 4.456 | 1.091 | 0.841 | 18 | 0.216 | 0.922 | 0 |
| Inventory
| 0 | 0 | -0.841 | 3.058 | 1.474 | 0.759 | 0 |
| Other Current Assets
| 26.22 | 15.055 | 5.878 | 3.201 | 1.634 | 0.985 | 2.272 |
| Total Current Assets
| 588.893 | 347.293 | 285.767 | 251.44 | 267.726 | 8.927 | 25.531 |
| Non-Current Assets: | |||||||
| Property, Plant & Equipment, Net
| 23.488 | 19.468 | 17.569 | 2.402 | 1.602 | 1.913 | 1.38 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 1.212 | 1.327 | 1.327 | 0.115 | 0.115 | 0.501 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 3.505 | 2.052 | 2.118 | 0.082 | 0 | 0 | 0 |
| Total Non-Current Assets
| 26.993 | 22.732 | 21.014 | 3.811 | 1.717 | 2.028 | 1.881 |
| Total Assets
| 615.886 | 370.025 | 306.781 | 255.251 | 269.443 | 10.955 | 27.412 |
| Liabilities & Equity: | |||||||
| Current Liabilities: | |||||||
| Account Payables
| 4.602 | 5.45 | 3.339 | 3.645 | 2.149 | 2.088 | 0.501 |
| Short Term Debt
| 1.978 | 1.005 | 0.91 | 1.724 | 0.846 | 0.376 | 0.166 |
| Tax Payables
| 0 | 0 | 0.05 | 0.11 | 0.185 | 0.043 | 0.284 |
| Deferred Revenue
| 0 | 0 | 0 | 7.135 | 4.394 | 1.915 | 10 |
| Other Current Liabilities
| 20.87 | 17.918 | 12.248 | 6.367 | 4.004 | 1.979 | 0.518 |
| Total Current Liabilities
| 27.45 | 24.373 | 16.547 | 11.846 | 7.184 | 4.486 | 11.469 |
| Non-Current Liabilities: | |||||||
| Long Term Debt
| 16.883 | 13.439 | 25.622 | 0.462 | 0.952 | 0.899 | 0.622 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0 | 0 | -12.811 | -0.231 | -0.414 | 5.075 | 2.563 |
| Total Non-Current Liabilities
| 16.883 | 13.439 | 12.811 | 0.231 | 0.538 | 1.018 | 3.185 |
| Total Liabilities
| 44.333 | 37.812 | 29.358 | 12.077 | 7.722 | 5.504 | 14.654 |
| Equity: | |||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 269.443 | 19.941 | 19.941 |
| Common Stock
| 0.004 | 0.003 | 0.002 | 0.002 | 0.002 | 0.002 | 0.001 |
| Retained Earnings
| -568.779 | -381.426 | -228.434 | -123.755 | -65.011 | -19.65 | -7.314 |
| Accumulated Other Comprehensive Income/Loss
| 0 | 0 | -0 | -0 | -269.443 | -19.941 | -0.246 |
| Other Total Stockholders Equity
| 1,140.328 | 713.636 | 505.855 | 366.927 | 596.173 | 25.1 | 0.376 |
| Total Shareholders Equity
| 571.553 | 332.213 | 277.423 | 243.174 | 261.721 | 5.451 | 12.758 |
| Total Equity
| 571.553 | 332.213 | 277.423 | 243.174 | 261.721 | 5.451 | 12.758 |
| Total Liabilities & Shareholders Equity
| 615.886 | 370.025 | 306.781 | 255.251 | 269.443 | 10.955 | 27.412 |